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Abstract
Background. The aim of the project was to identify risk factors associated with visual progression and treatment 
indications in pediatric patients with neurofibromatosis type 1 associated optic pathway glioma (NF1-OPG).
Methods. A multidisciplinary expert group consisting of ophthalmologists, pediatric neuro-oncologists, neuro-
fibromatosis specialists, and neuro-radiologists involved in therapy trials assembled a cohort of children with 
NF1-OPG from 6 European countries with complete clinical, imaging, and visual outcome datasets. Using methods 
developed during a consensus workshop, visual and imaging data were reviewed by the expert team and analyzed 
to identify associations between factors at diagnosis with visual and imaging outcomes.
Results. Eighty-three patients (37 males, 46 females, mean age 5.1 ± 2.6 y; 1–13.1 y) registered in the European 
treatment trial SIOP LGG-2004 (recruited 2004–2012) were included. They were either observed or treated (at diag-
nosis/after follow-up).
In multivariable analysis, factors present at diagnosis associated with adverse visual outcomes included: mul-
tiple visual signs and symptoms (adjusted odds ratio [adjOR]: 8.33; 95% CI: 1.9–36.45), abnormal visual behavior 
(adjOR: 4.15; 95% CI: 1.20–14.34), new onset of visual symptoms (adjOR: 4.04; 95% CI: 1.26–12.95), and optic at-
rophy (adjOR: 3.73; 95% CI: 1.13–12.53). Squint, posterior visual pathway tumor involvement, and bilateral pathway 
tumor involvement showed borderline significance. Treatment appeared to reduce tumor size but improved vision 
in only 10/45 treated patients. Children with visual deterioration after primary observation are more likely to im-
prove with treatment than children treated at diagnosis.
Conclusions. The analysis identified the importance of symptomatology, optic atrophy, and history of vision loss 
as predictive factors for poor visual outcomes in children with NF1-OPG.
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Key Points
1.  This analysis of risk factors for visual deterioration in patients with NF1-OPG was 
carried out using data from a European trial of chemotherapy.
2.  Symptomatology, optic atrophy, and history of vision loss predict poor visual 
outcomes in NF1-OPG.
3.  Treatment early after visual deterioration is more likely to salvage visual acuity.
Neurofibromatosis type 1 (NF1) is a genetic tumor predis-
position syndrome with an incidence of less than 1:3000.1 
About 15% of NF1-affected children develop optic pathway 
gliomas (OPGs) during childhood, usually presenting during 
the first decade of life and occasionally in the second.2 
Approximately 40% of OPG patients develop visual symp-
toms, but only about 15% of all OPG patients are treated.3–7 
This visual risk is unpredictable, justifying regular oph-
thalmic screening during infancy and early childhood, 
although asymptomatic screening with MRI remains contro-
versial.2,5,6,8–13 Data on the natural history and visual risk fac-
tors in children with NF1-OPG are scarce.3,5,6,10,14
Factors influencing visual outcome have been investigated 
only retrospectively, identifying age, tumor extension to the 
optic tracts, optic disc pallor, and young age as possible risk 
factors correlated with poor visual outcome.6,8,14,15 Other 
data suggest that girls with isolated optic nerve glioma have 
a higher risk for visual loss; however, visual outcomes after 
treatment do not differ from boys.6,16
Fisher et  al reported a retrospective US multicenter 
analysis of visual outcome in 88 children treated with che-
motherapy for NF1-OPG, showing improvement of visual 
acuity (VA) in 32%, worsening in 28%, while 40% remained 
stable.6 Visual and imaging outcomes were dissociated, 
consistent with previous observations.17–19
The SIOP-LGG-2004 trial recorded visual data in <25% 
of children with NF1-OPG; no visual data were reported 
in the Children’s Oncology Group (COG) A9952 study.20,21 
This justifies consideration of developing criteria for treat-
ment indication, outcome assessments, and effectiveness 
of treatments,6,8,18,22 which have now been acknowledged 
in upcoming trials in NF1 where methods for measuring 
visual outcomes are now specified using the experience of 
this project as basis (eg, ACNS1831, LOGGIC).
We report the results of a multidisciplinary international 
workshop held in Nottingham, UK, April 10–11, 2014 and fo-
cusing on childhood NF1-OPG. The European Society for 
Paediatric Oncology (SIOPE) LGG NF1 subgroup addressed 
previous inconsistencies of trial methods including their ex-
perience of the SIOP LGG 2004 trial. It was decided to vali-
date current methods of assessing vision and imaging and 
to develop a European consensus on criteria for treatment 
indication and patient selection for future trials. The overall 
purpose was to use this experience to refine trial design for 
studying the natural history of this disease, identify possible 
risk factors for visual progression, and allow direct compar-
ison of new drug treatments directed at preserving vision.
Methods
Trial Patient Cohort
A convenience cohort of trial’s patient data was assem-
bled and analyzed to discern factors determining the risk of 
tumor and visual response/progression.
Workshop Methodology
The workshop was attended by 28 participants (ophthal-
mologists, pediatric neuro-oncologists, neurofibroma-
tosis specialists, and neuro-radiologists) from 9 SIOPE 
centers (Austria: Vienna; Denmark: Copenhagen; France: 
Villejuif; Germany: Berlin, Hamburg; Italy: Padua; UK: 
Leeds, London, Nottingham). Participating centers were 
asked to retrieve data on children with NF1-OPG who had 
previously been enrolled in the institutional review board–
approved LGG 2004 trial and for whom a complete clin-
ical, visual outcome, and imaging dataset was available. 
It was intended to obtain a balanced mix of patients of 
different age groups (<3 y, 3–6 y, and >7 y) and various 
clinical course (observation only/observation followed by 
treatment/treatment at diagnosis). Mandatory visual data 
Importance of the Study
As prospective data on an appropriate risk stratifi-
cation for vision loss in children with NF1-OPG are 
lacking, an international panel of experts in the field 
analyzed risk factors for visual deterioration in a large 
European trial cohort. The identification of patients at 
risk for vision loss will help to discern children with NF1-
OPG to be observed from those in need of treatment. 
Symptomatology, optic atrophy, and history of vision 
loss could be identified as predictive factors for poor 
visual outcomes in children with NF1-OPG. Children 
with visual deterioration after primary observation are 
more likely to improve after treatment than children 
treated at diagnosis. This suggests a benefit for close 
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included VA and fundoscopic examination at the following 
time points: (i) OPG diagnosis, (ii) at start of treatment (if 
treated), (iii) at the end of treatment (if treated), or (iv) after 
18 months from diagnosis if only observed. Presence of 
optic atrophy and further ophthalmologic signs (squint, 
proptosis, nystagmus, papilledema, abnormal visual be-
havior) as well neurologic signs and symptoms (eg, ele-
vated intracranial pressure) were also noted. The term 
“abnormal visual behavior” used in the LGG 2004 trial 
protocol reflects the clinical overall impression of dis-
turbed vision based upon history and parental observation 
in the absence of objective VA measurements due to the 
young age or poor cooperation.
Radiology
The tumors were identified using a combination of T2/fluid 
attenuated inversion recovery (FLAIR) and post gadolinium 
T1-weighted imaging. As contrast enhancement was variable 
and sometimes absent, and tumoral enhancement often fluc-
tuates during the course of the disease both with and without 
treatment, T2/FLAIR data were used to define the full extent 
of the tumor. The T2 and FLAIR images were also the constant 
set of sequences available in all patients, and were therefore 
the basis for sequential study evaluations. Progression was 
determined by combining T2/FLAIR information with new or 
extending/enlarging T1 enhancing abnormality.
Where lesions were measurable, the measurements 
were used for sequential evaluations. More diffuse and 
ill-defined tumor involving the posterior visual pathways 
was less amenable for reliable and repeatable linear meas-
urements. This is recognized as a methodological flaw. 
Tumor volumetric evaluation was not undertaken due to 
inherent difficulties defining tumor margins on T2/FLAIR 
images (often ill-defined) and separating the tumor from 
contiguous NF1-related focal areas of signal intensity. In 
addition, for the T2/FLAIR imaging, the slice thickness (usu-
ally 5 mm or, in some cases, 6 mm) and slice gap (usually 
1.5 mm or more) precluded useful volumetric evaluation. 
Volumetric techniques for assessing ill-defined multifocal 
T2/FLAIR lesions have as yet not been fully validated, 
with ongoing work at developing appropriate software 
programs to enable reliable and auditable volumetric 
measurement. Involvement of the hypothalamus and pres-
ence of hydrocephalus were routinely recorded.
The radiology consensus work group also unified the 
terminology used to describe the anatomic pattern of NF1-
OPG by using the classic Dodge and modified Dodge clas-
sification (MDC).
Ophthalmologic Data
Visual acuity data were reported as LogMAR units, in 
order to ensure a quantitative and continuous measure 
as a surrogate marker of visual function, with higher 
LogMAR values corresponding to worse VA. As the VA 
testing methods varied, VA was converted from different 
grading systems (eg, decimal) to LogMAR. Prespecified 
values were used to describe qualitative VA (eg, “hand 
movement,” “light perception”). VA was depicted on a 
chart with axes corresponding to the right/left eye respec-
tively (Fig.  1A). A  graphical representation of different 
colors corresponding to different visual risk zones in both 
eyes was introduced and adapted subsequently by one of 
the authors (E.O.) from World Health Organization (WHO) 
categories of visual impairment.23,24 Changes over time 
were evaluated using this proposed visual risk assess-
ment system and by analysis of VA data of single eyes as 
proposed previously.6 It was not possible to include visual 
field data as part of the workshop due to the young age of 
the patients and the lack of observation data for review.
Appropriate methods adjusting for the age-related visual 
maturation are lacking. A clinical follow-up chart was also 
developed and shared with the review group and gained 
support as it permitted recording of VA of the right and left 
eye over time, comparison against age-appropriate normal 
values across infancy and early childhood, and grading of 
vision loss (Fig. 1B). In addition, for data analysis, visual 
function at the end of follow-up was classified by clinicians 
as “better,” “same,” or “worse” reflecting the subjective im-
pact of VA change. The trial did not specify the requirement 
for visual field data because of the difficulties of making 
such measurements reliably in the very young age group 
who typically present with this tumor type.
Statistical Analysis
The online datasets were reviewed and approved by par-
ticipants of the radiology and ophthalmology working 
groups. Descriptive analysis was used to characterize 
the study population. As appropriate, t-test, chi-square, 
or Fisher’s exact test was used for comparison between 
groups. Odds ratios (ORs) with 95% confidence intervals 
were calculated for each variable using logistic regres-
sion to identify potential predictors. All analyses were 
performed with SPSS 23 for Windows, and P < 0.05 was 
considered statistically significant in all analyses.
Results
The NF1-OPG Workshop Cohort
The cohort for analysis consisted of 83 patients (37 males, 46 
females) with a mean age (at first imaging assessment) of 
5.1 ± 2.6 years (range, 1–13.1 y). Patient characteristics, clin-
ical history, and symptoms preceding diagnosis are shown 
in Supplementary Table 1. In approximately half of the pa-
tients (39/83, 47%) an OPG had been detected during MRI 
screening. All patients had a visual and imaging assessment 
before commencement of treatment or observation. Mean 
follow-up time, defined as the interval between the first and 
last assessment (either vision or imaging) was 3.4 ± 2.7 years.
Visual Assessment at Baseline
Forty-three children (52%) were asymptomatic, while 25 
(30%) had 1 symptom and 15 children (18%) had mul-
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symptoms presented in over 10% of patients included 
squint (22/83, 27%), abnormal visual behavior (19/83, 
23%), and proptosis (11/83, 13%). Based on the visual 
function classification (Fig. 1A) agreed by the workshop 
participants, 44% (n = 36) of patients were classed as 
normal/near normal vision, 36% (n = 29) as mild/mod-
erate, and 20% (n = 16) as severe/profound visual impair-
ment. About a third (29/83, 35%) had optic atrophy (14 
unilateral and 15 bilateral).
Imaging Assessment at Baseline
Distribution of anatomic site at diagnosis followed cen-
tral review. Using the classic Dodge system,25 there were 
42% (n = 35) stage A; 19% (n = 16) stage B, and 39% (n = 32) 
stage C (Fig. 2A). When classified according to the MDC26 
in 31 children (37%) tumor extended posterior to the 
chiasm (MDC 3/4), and in 76% (63/83) the OPG was bilateral 
(Fig. 2B, C and Supplementary Table 1).
Management Strategy
Overall management strategy and visual and radiological 
outcomes are summarized in Fig. 3. Sixty patients (72%) 
were initially observed after diagnosis, of whom 38 re-
mained in observation throughout the follow-up period 
and 22 subsequently started treatment. Twenty-three pa-
tients (28%) started nonsurgical treatment at diagnosis, 
while 1 changed to second chemotherapy due to progres-
sive vision loss.
Justification of Selecting Treatment versus 
Observation
Among the 45 patients receiving treatment at diagnosis 
or after observation, the reasons to treat as well as prior 
visual and imaging assessments are summarized in 
Supplementary Tables 1 and 2. The most common indi-
cation for initial observation was normal or acceptable 
  




































































































































































































































0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
CHEMOTHERAPHYCHEMOTHERAPHY
Visual acuity, left eye Visual acuity, left eye
95% lower limits, Teller Acuity Cards (Mayer et al) 95% lower limits, Teller Acuity Cards (Mayer et al)
95% lower limits, ETDRS/HOTV logMAR (Leone et al) 95% lower limits, ETDRS/HOTV logMAR (Leone et al)
Visual acuity, right eye Visual acuity, right eye
95% lower limits, Teller Acuity Cards II (Leone et al) 95% lower limits, Teller Acuity Cards II (Leone et al)
95% lower limits, ATS HOTV single letters (Leone et al)
95% lower limits, ATS HOTV single letters (Leone et al)
95% lower limits, Teller Acuity Cards corrected for TACII (Clifford et al) 95% lower limits, Teller Acuity Cards corrected for TACII (Clifford et al)
B
A
Fig. 1 Proposed graphical scheme for visualizing visual acuity measurement. (A) Visual function classification and a schematic for recording VA 
results.24 (B) Clinical follow-up record for NF1-OPG patients. Left: This graph portrays the longitudinal visual acuities of a young boy diagnosed at 
the age of 2 years 7 months old. Where the line is green, both eyes have the same visual acuity. Right: Longitudinal visual acuities of a young patient 
diagnosed at the age of 2 years and 2 weeks old. The red circles on the graph indicate the structures involved and the blue squares indicate hypo-
thalamic involvement. The 95% lower limits of VA testing in young children are provided as published previously.35–37 CF: count fingers; HM: hand 







/neuro-oncology/advance-article/doi/10.1093/neuonc/noaa153/5867970 by guest on 26 August 2020








vision (n = 32), followed by lack of other visual symptoms 
(n = 16). Other reasons (n < 10) included unilateral visual 
deficit (n = 7), no threat to vision (n = 5), and stable vision 
(n = 4). Conversely, reasons to treat at diagnosis were 
preexisting severe vision loss and/or actual threat of vision 
loss, while indications after initial observation were pro-




Modified dodge classification (PLAN)
A: 42% (n=35)
Bilateral tumour involvement
1b: 51% (n = 42)
1c: 63% (n = 52)
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Dodge classification
Fig. 2 Distribution of anatomic site at diagnosis following central review. (A) Dodge27 and (B) MDC28; (C) bilateral involvement PLAN 1b, 1cB, 1cb, 
2a, 2b, 3B, 3b, 4B, and 4b. In the MDC, all involved locations are stated, most tumors have more than one involved location, therefore percentages 
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In order to identify clinical characteristics associated with 
the decision to treat, we compared patients in the obser-
vation group throughout the follow-up period (n = 38) and 
those who had treatment (n = 45) (Supplementary Figure 1). 
Patients in the treatment group were more likely to be young 
children aged 2–5  years at diagnosis (27/45), to have new-
onset visual symptoms (17/45), visual impairment classed as 
severe/profound (16/45), abnormal visual behavior (15/45), 
multiple visual symptoms (13/45), bilateral optic atrophy 
(12/45), and/or proptosis (10/45) (Supplementary Figure 1). 
A similar pattern was also observed when we further divided 
the subgroup according to the time point of treatment, ie, 
at diagnosis or after observation (Supplementary Table 1). 
Among patients who were originally observed after diag-
nosis (n = 60), 2 or more visual symptoms and severe visual 
impairment at diagnosis were factors which were signifi-
cantly overrepresented in those who ultimately started treat-
ment at a later stage (Supplementary Table 1). At the start of 
treatment, VA was better in patients being observed first com-
pared with patients initially treated at diagnosis (P = 0.046).
Visual Outcome
Among the study population, 19 patients (23%) presented 
with VA of LogMAR ≥ 1.0 at diagnosis (16 unilateral and 3 
bilateral), and this number increased to 28 (21 unilateral 
and 7 bilateral) at last follow-up.
For overall visual changes, as assessed clinically 
(Fig. 3), at the end of follow-up/treatment 54 out of 83 
patients (65%) had better (n = 14) or the same vision 
(n  = 40) compared with baseline assessment and 29 
(35%) became worse (5 in observation group and 24 in 
treatment group; Fig.  3). Visual outcomes did not cor-
relate with radiological changes (Fig.  3); for instance, 
18/45 patients showed improvement in MRI after treat-
ment but only 3 actually had better vision. The strongest 
correlation was static vision and stable imaging in the 
observation group. Age at which patients started treat-
ment was not associated with difference in visual out-
come (P = 0.88).
Classification by visual risk zones at diagnosis, pretreat-
ment, and post-observation or end of treatment is shown 
in Fig. 4. Only 9 out of the 45 patients who received treat-
ment moved up one (n = 8, 5 initially observed) or two (n 
= 1) risk zone categories compared with their pretreatment 
assessment (43 valid pairs), while the rest remained in the 
same category (n = 25, 12 initially observed) or became 
worse (n = 9, 4 initially observed).
At the individual level (Fig.  5), 154 eyes in 77 pa-
tients were eligible for analysis. Visual acuity remained 
unchanged in the observation only group (Fig.  5A). 
  
Eligible NF1 OPG cases (n = 83)
Management decision after diagnosis or initial surgery
Observation (n = 60)
Remained in





Improvement (n = 12)
No change (n = 22)







1 (3%) 9 (24%) 2 (5%)
2 (5%)
1 (3%)3 (8%)0 (0%)





Response (n = 18)
No change (n = 24)







3 (7%) 4 (9%) 11 (25%)
11 (25%)
2 (5%)00







Treatment at diagnosis (n = 23)
Chemotherapy n = 22*
Interstitial radiotherapy n = 1
Treatment after observation (n = 22)
Chemotherapy n = 21
Interstitial radiotherapy n = 1
Chemotherapy n = 43
Interstitial radiotherapy n = 2
Any treatment (n = 45)
Fig. 3 Summary of management strategy, visual, and radiological outcomes of the Nottingham Workshop cohort (n = 83). Vision at last follow-up 
was judged as better, same, or worse by clinical judgment of trial physicians in the trial center. *One patient changed initial treatment to second 
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Compared with patients treated at diagnosis, children 
treated after observation less frequently developed further 
vision loss of 2 lines (0.2 LogMAR) or more (12 eyes in 8/21 
patients vs 19 in 14/21) or dropped to near-blindness/blind-
ness (2 eyes in 2/21 patients vs 11 in 10/21), indicating a 
better overall visual status at end of treatment (Fig. 5B, C. 
Of 16 patients worsening during observation, 7 had visual 
deterioration reversed with vincristine/carboplatin (VC) 
(Fig. 5D).
Potential Risk Factors for Visual Deterioration
Descriptive and univariate analyses were carried out to 
identify potential predictors of visual deterioration from 
the first assessment (Supplementary Table 3). Strong risk 
or protective factors with their crude ORs and adjusted 
ORs are summarized in Table 1. After adjustment for age at 
diagnosis, sex, and management strategy (ie, observation, 






























































































































































0.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.6
0.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.6
0.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.60.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.6
0.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.6 0.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.6
0.8 0.6 0.4 0.2 0.01.01.21.41.6>1
.6
Pre-observation  (n = 38) Pre-treatment  (n = 22) Post-treatment  (n = 23)
Post-treatment  (n = 22)
Fig. 4 Comparison of visual function classification at pre-observation, pretreatment, and post-observation/treatment. Visual function classifica-
tion: normal/near normal (green); mild/moderate impairment (amber); severe profound impairment (red). Count fingers, hand movement; light per-
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variables remained significant (P < 0.05) and were: pres-
ence of more than one visual symptom (adjOR: 8.33; 95% 
CI: 1.9–36.45), abnormal visual behavior (adjOR: 4.15; 95% 
CI: 1.20–14.34), new onset of visual symptoms (adjOR: 4.04; 
95% CI: 1.26–12.95), and optic atrophy (adjOR: 3.76; 95% 
CI: 1.13–12.53). Squint, posterior tumor involvement (MDC 
3/4), and bilateral tumor involvement showed borderline 
significance (P-values between 0.05 and 0.1), with adjOR 
ranging between 2.9 and 3.50. Optic atrophy indicates neu-
ronal loss, this study has not clarified its role in predicting 
vision change. We also tested a potential risk assessment 
model based on the variables selected from the workshop 
discussion (Supplementary Table 4). Although this model 
had an overall accuracy of 82.4%, the estimates were un-
stable due to the small sample size and number of vari-
ables in this model.
Discussion
The 2 major collaborative scientific groups, the SIOPE and 
the COG, like others, have been to date unsuccessful in 
gathering and adequately reporting visual outcome data 
from large prospective trials enrolling patients with NF1-
associated OPG.20,21,27–29
Justification Workshop
Preliminary analysis of visual data from the SIOP-LGG 
2004 trial followed by the process of designing the 
next generation of NF1-OPG trials highlighted this de-
ficiency.20 The visual outcomes of the UK cohort of the 
trial have recently been published.14 Even with this sig-
nificant effort, sufficient ophthalmological data could 
only be gathered for little more than half of all OPG pa-
tients. In response, this multidisciplinary workshop was 
conducted in order to discuss and develop a new con-
sensus for visual and radiographic assessment criteria 
for future trials in Europe. Identification of visual risk fac-
tors and harmonization of appropriate eligibility criteria 
and outcome measures are of particular importance in 
view of the possible introduction of new targeted drugs 
(eg, MEK inhibitors), as potential first-line treatment 
in patients with NF1-associated LGG compared with 
standard chemotherapies in upcoming trials. A  retro-
spective study conducted by Fisher et al among expert 
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Fig. 5 Visual acuity outcome between initial and post-observation/treatment assessment at individual level (154 evaluable eyes in 77 patients). 
Visual acuity outcome per eye for patients in (A) observation only, (B) treatment at diagnosis, (C) treatment after observation, and (D) summary of 
visual acuity outcome of all 77 patients. CF: count fingers, HM: hand movement, LP: light perception; NLP: no light perception. *“Improvement”/ 
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practitioners from several large neuro-oncology centers 
concluded that there was a lack of agreement on how to 
select patients for treatment or observation.6 In contrast 
to this retrospective data report, the present workshop 
was conducted with specific consensus methodology 
and was based on a selection of cases recruited within 
a prospective clinical trial at large international centers 
over a short time period. Furthermore, in the SIOP LGG-
2004 trial, the reasons for initiating treatment including 
severe symptoms or vision loss, documented tumor pro-
gression on imaging, progressive vision loss, or threat 
to vision were prespecified. One notable difference be-
tween these 2 convenience cohorts is the median age 
at presentation. The Fisher cohort was 2.66 years, while 
this cohort median age was 4.7  years. Fisher’s cohort 
was recruited from institutional clinics indicative of cur-
rent practice in the US. This cohort was recruited from a 
multicenter clinical trial according to a consensus-based 
selection criteria in Europe. The differences are likely to 
be due to referral bias and clinical practice norms in dif-
ferent health systems. The differences are important to 
consider in designing future trials, as such a significant 
difference in age at presentation will influence tumor be-
havior, suitability of drug preparations, and the capacity 
to comply with outcome assessments.
Study Cohort
The establishment of a convenience patient cohort, using 
prospectively collected complete clinical, visual, and im-
aging trial datasets overcame the inconsistencies of data 
for imaging and visual assessment methods in previous 
trials or retrospective studies. The use of trial patients har-
nessed existing ethical approvals for international collabo-
ration and permitted representative case selection across 
age, vision, and imaging categories. The visual outcome 
datasets and images were reviewed centrally by special-
ists working in pairs. The process of central review of all 
imaging and visual outcome data permitted an in-depth 
assessment of the need for consistency of such data re-
porting and refinement of both the imaging and visual out-
come methods. A  consensus on both standardization of 
recording visual outcome as well as conversion to LogMAR 
scores (Fig. 1) was reached, and presentation of these data 
in a standardized format integrating WHO visual outcome 
criteria was agreed (see Appendix 1). The methods for out-
come from a European perspective have already been fed 
into the transatlantic discussions of trial design that are 
active.30
Imaging Consensus
The imaging group tested the application of the MDC 
as a way of anatomically classifying the tumor distribu-
tions.26 Furthermore, the imaging group concluded that 
tumor response criteria could not be based upon tumor 
or optic pathway measurement according to progres-
sion of MDC stage (Supplementary Figure 2) and would 
need to be based upon overall opinion of the imaging ap-
pearances to represent “progression,” “stable disease,” 
or “response.” Experience gained in this way will set the 
foundation for future trial design and as the basis of plans 
for the next era of trials that will aim at improving func-
tional outcomes.30
  
Table 1 Risk factors for visual deterioration after observation or treatment 
 Crude OR  
(95% CI)
Adjusted OR  
(95% CI)*
P-value
Risk factors, crude OR > 5  
  Two or more visual symptoms at initial visual assessment:  
squint, abnormal visual behavior, proptosis, nystagmus, papilledema
17.50 (3.98–76.88) 8.33 (1.90–36.45) 0.005
 Bilateral optic atrophy 9.75 (2.62–36.34) 5.15 (1.21–21.96) 0.027
 Optic atrophy (unilateral + bilateral) 6.91 (2.39–19.95) 3.76 (1.13–12.53) 0.031
 Severe/profound visual impairment (red) 6.91 (1.87–25.49) 1.74 (0.32–9.35) 0.518
 Abnormal visual behavior 6.50 (2.12–19.94) 4.15 (1.20–14.34) 0.025
 New onset visual symptoms 6.16 (2.16–17.54) 4.04 (1.26–12.95) 0.019
Risk factors, crude OR 3–5      
 Unilateral optic atrophy 4.88 (1.34–17.79) 2.68 (0.61–11.79) 0.191
 Squint 4.06 (1.46–11.31) 3.19 (0.99–10.28) 0.052
 Bilateral tumor involvement 3.98 (1.06–15.00) 3.50 (0.81–15.06) 0.092
 Proptosis 3.98 (1.06–14.99) 2.05 (0.48–8.87) 0.336
 Posterior involvement (PLAN 3/4) 3.20 (1.25–8.22) 2.90 (0.99–8.53) 0.053
Protective factors, crude OR < 0.5      
 NF1 screening with imaging 0.36 (0.14–0.93) 0.77 (0.25–2.34) 0.638
* Summary of crude and adjusted odds ratios for variables reached P < 0.1 in univariate analysis (Supplementary Table 3), ranked by effect size. 
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Cohort Analysis of Visual Risk
Finally, this comprehensive dataset permitted univariate 
and multivariate analyses of risk factors for visual and im-
aging outcomes in patients selected initially for observa-
tion versus those selected for initial treatment, based upon 
the LGG 2004 trial treatment. Compared with the results 
of Fisher’s US study6 and the national UK cohort,14 this 
European dataset confirmed that only a minority of patients 
(9/45, 20%) experience visual improvement after VC treat-
ment. The previously recognized lack of correlation between 
vision and imaging outcomes has been replicated in this 
study. Factors that identify children with the greatest risk 
of vision loss and need for therapy include the presence of 
multiple visual symptoms, optic atrophy, abnormal visual 
behavior, and new onset of visual symptoms. In contrast to 
the study by Fisher, neither age at diagnosis nor anatomic 
features of modified Dodge categories 3 and 4 involving 
posterior tracts and radiations were of significance. The 
small sample size and short follow-up make this unique and 
contrasting finding worthy of further confirmation in future 
prospective studies to clarify its status as a predictive factor. 
The Fisher cohort and this cohort were both convenience co-
horts. In Fisher’s cohort the age at diagnosis was a median 
of 2.66 years compared with a median age of 4.7 years in 
this cohort. Fisher’s cases were identified from participating 
hospitals from clinical databases where chemotherapy had 
been used (oncology, ophthalmology, neurology, and/or NF 
clinic) at each site. This cohort was derived from cases en-
tered into an international trial. Their differences limit the va-
lidity of close comparison.
Treatment versus Observation Criteria
In accordance with literature, progressive vision loss, pres-
ence of multiple visual symptoms, and tumor progression 
on imaging were the main reasons to initiate treatment.6–8 
Among 60 patients, selected initially for observation, 22 
(37%) developed visual deterioration and were then treated. 
They showed a similar pattern of visual symptoms, but 
better VA than those selected initially for treatment. The mul-
tivariate analysis of factors associated with visual outcome 
helps to identify characteristics suitable for case selection 
for observation versus treatment, which need further valida-
tion. A strategy incorporating patient history, visual function, 
and imaging will be necessary to correctly select patients for 
treatment.31 Further work to be published has explored ex-
pert clinical justification of case selection for initial obser-
vation and immediate treatment (Walker et  al manuscript 
in preparation). It is not possible from the data collected in 
the trial, and therefore available in this analysis, to identify 
whether the patients initially observed and who went on to 
be treated were identified with different imaging strategies 
or symptom types/severities compared with those who 
were initially treated. This was the local physician’s decision 
supported by the trial’s eligibility criteria.
Sight-Saving Therapy
New sight-saving/-preserving therapies need to be tested 
in NF1-OPG patients with greatest need for therapy to 
ensure that new treatments are truly tested for their vision-
saving qualities. It is notable that in this workshop NF1 co-
hort, for those treated with VC, visual improvement was 
observed in a minority (Figures 4 and 5). Yet, the analysis of 
visual outcomes demonstrates that patients treated imme-
diately or after observation had different patterns of visual 
response and severity of visual outcome. Those treated 
immediately had a smaller proportion of patients experi-
encing stable disease/visual improvement and a greater 
proportion with very severe vision loss compared with 
those treated after a period of observation This observation 
suggests that history of recent vision loss plays an impor-
tant role in selecting cases with potential for visual stability 
or improvement and is associated with a lower risk of very 
severe visual outcome. VC would seem to be most effec-
tive in reversing vision loss when used before the vision 
loss is established. The poor outcome for patients with 
optic atrophy would support this observation indicating 
that vision recovery cannot be expected once neuronal 
loss becomes established.
As a consequence, we propose that eligibility criteria for 
future trials should include evidence, and timing, of prior 
visual decline, where it can be identified, as a factor for 
case selection for treatment and in analysis of visual out-
comes. The role of optic atrophy could be better explored 
using optical coherence tomography, where retinal fiber 
layer thickness correlates with neuronal loss, offering a 
more objective measure of optic pathway injury as an out-
come measure for early intervention trials.32,33
Our findings suggest that, for many, treatment may be 
starting when nerve damage has already occurred and be-
come irreversible and that VC is only preserving, rather 
than improving, vision.18 It also justifies more detailed 
consideration of the mechanisms of vision loss and thera-
peutic impact of treatment(s) under trial. The goal is to re-
store, or at least preserve, optic nerve function.
One factor to be considered is the continued use of any 
drug with known neurotoxicity, such as weekly vincris-
tine. Vincristine has a protracted half-life of about 5 days, 
making weekly scheduling lead to accumulation of tissue 
levels. Vincristine peripheral neuropathy is a recognized 
complication of weekly scheduling necessitating dose re-
duction or cessation of therapy. A recent case report and 
literature review identifies 12 cases, 9 in children (age <18 
y) with optic atrophy and blindness after the use of vincris-
tine for various cancer therapies.34 The COG A9952 study 
reported grade 3 and 4 neurotoxicity in 23% of NF1 pa-
tients receiving VC, which included weekly vincristine in 
induction.21 This drug combination, while standard, has 
never been tested in a randomized comparison and so is 
the de facto, rather than the tested, standard treatment. 
Reconsideration of vincristine dosing and scheduling may 
be justified.
Observation Strategy
The role of monitoring asymptomatic children with 
NF1 by prediagnostic MR imaging of the brain is dis-
puted.2,9–13 The present analysis revealed that pa-
tients who had MRI as part of surveillance were at a 
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analysis (crude OR: 0.36; 95% CI: 0.14–0.93) but not in the 
multivariable analysis (adjOR: 0.77, 95% CI: 0.25–2.34). 
Novel MRI techniques such as fractional anisotropy and 
MRI volumetry of the optic pathway in conjunction with 
optical coherence tomography may help identify preclin-
ical signs of neuronal loss and therefore those at higher 
risk for visual deterioration, which may justify changes 
to screening guidelines.31 Confirmation in population 
trials is needed especially if new treatments were dem-
onstrated to be less toxic and more effective than current 
approaches with chemotherapy.
Conclusion
This workshop has refined understanding of risk factors 
for visual deterioration and therefore case selection for 
“observation” versus “treatment.” This work will assist 
with identifying criteria associated with the highest risk of 
visual deterioration and so the candidates most suitable 
for evaluating new drugs and their capacity to preserve or 
save vision.
Supplementary Material
Supplementary data are available at Neuro-Oncology 
online.
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